We have initially applied See-TX to selective protein misfolding diseases and have targeted lysosomal enzyme, to address the unmet medical needs of rare and neurodegenerative

What is allostery? Allo comes from the Greek allos which meaning “other.” Allosteric binding describes a ligand that binds a protein at a target site

When was Alzheimer’s disease discovered? Alzheimer’s disease as we know it was first described by Dr. Alois Alzheimer, a German doctor, in 1906. He was

Alpha-synuclein is a neuronal protein that regulates trafficking and neurotransmitter release. Aggregation of alpha-synuclein is associated with the formation of lewy bodies, which are protein

Krabbe disease is a devastating disease that belongs to the Leukodystrophy disease family. These diseases are characterized by defects in the myelin, an insulating layer

Gaucher Disease and Parkinson’s Disease are two distinctly different diseases in terms of their onset, symptoms, and prognosis. Despite these differences these diseases have one

Discovering treatments for patients that currently have no available disease-modifying options is the priority of Gain Therapeutics. Specifically, there is a large unmet need for

Enzyme Targeting: Over the last few years, diseases caused by dysfunctional or missing enzymes have been treated with a type of therapy called enzyme replacement

Gain Therapeutics targeting allosteric sites: Traditional small molecule drugs work by targeting an active binding site. Gain Therapeutics is focused on targeting allosteric binding sites,

Why is the AlphaFold DataBase exciting? DeepMind created the artificial intelligence system, AlphaFold, to predict the three-dimensional (3D) structure of thousands of proteins and compiled

What is DeepMind? Deepmind AlphaFold protein folding structure prediction: DeepMind is a company that combines a variety of disciplines to develop artificial intelligence (AI) technology

Genetic mutations are one of the most common causes of serious diseases. When genes are mutated it can affect the function of proteins which oftentimes

Designing therapeutics that target cellular proteins can be difficult due to the lack of specific binding sites or the potential for disrupting the normal protein

Parkinson’s Disease is among the most common degenerative brain disorders, affecting millions of people each year in the United States alone. We know that the

On September 30th, 2021 Gain Therapeutics presented at the Cantor Fitzgerald virtual global healthcare conference. Eric Richman, CEO and Manolo Bellotto, GM and President, sat

MJFF 2021 Conference: What is Gain Therapeutics Presenting at the MJFF 2021 Parkinson’s Disease Therapeutics Conference Webinar? This year due to the impact of the

Allosteric Binding Sites: One of the most prevalent issues in drug discovery and development is the difficulty to find novel drug targets. Majority of disease-causing

Gain Therapeutics’ SEE-Tx patented algorithm provides quantitative predictions of druggable binding hot spots based on changes in binding free energy (ΔG). No other company has

MJFF 2021 Conference: The Michael J. Fox. Foundation (MJFF) has held a Parkinson’s Therapeutics Conference annually every fall, starting from 2009. Due to the COVID-19

Gain Therapeutics’ physics-based screening platform is able to identify previously unknown binding pockets on well-validated protein targets by identifying cavities on the surface and in

On April 20th, 2021, Gain Therapeutics announced a multi-target drug discovery and development deal with Zentalis Pharmaceuticals to identify and address novel oncology targets.  ​​Gain

At Gain Therapeutics, we are uniquely positioned to capitalize on the AlphaFold project and
extend the scope of our existing technology.

Just last month, AlphaFold launched their Protein Structure Database, containing high-quality predicted structures of every protein in the human body.

For years, the neuroscience industry has been plagued by a high failure rate of drugs in the clinical stages.

“We were thrilled to complete our IPO in March on the Nasdaq Global Market Exchange,” stated Sal Calabrese, Chief Financial Officer of Gain.

Gain Therapeutics, Inc. is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted

BETHESDA, Md., June 10, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and